

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 March 2001 (08.03.2001)

PCT

(10) International Publication Number
WO 01/15677 A2(51) International Patent Classification⁷: A61K 31/00,
31/498, A61P 27/16Donnybrook Drive, Burleson, TX 76028 (US). SHARIF,
Najam, A. [US/US]; 7 Courtney Court, Arlington, TX
76015 (US).

(21) International Application Number: PCT/US00/22764

(22) International Filing Date: 18 August 2000 (18.08.2000)

(74) Agents: YEAGER, Sally, S. et al.; Alcon Research, Ltd.,
R & D Counsel, Mail Code Q-148, 6201 South Freeway,
Fort Worth, TX 76134 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AU, BR, CA, CN, JP, MX,
PL, TR, US, ZA.(30) Priority Data:
09/387,358 31 August 1999 (31.08.1999) US(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).(71) Applicant (*for all designated States except US*): ALCON
LABORATORIES, INC. [US/US]; 6201 South Freeway,
Mail Code Q-148, Fort Worth, TX 76134 (US).

Published:

— *Without international search report and to be republished
upon receipt of that report.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GAMACHE,
Daniel, A. [US/US]; 5610 Hunterwood Lane, Arling-
ton, TX 76017 (US). YANNI, John, M. [US/US]; 2821*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 01/15677 A2

(54) Title: USE OF 5-HT_{1B/1D} AGONISTS TO TREAT OTIC PAIN(57) Abstract: Compositions and methods for treating otic pain are disclosed. In particular, the invention discloses compositions and methods of using 5-HT_{1B/1D} agonists for the prevention or alleviation of otic pain.

WO 01/15677

PCT/US00/22764

Use of 5-HT_{1B/1D} Agonists to Treat Otic Pain

5

The present invention relates to the pharmaceutical treatment of otic pain. In particular, the present invention relates to the topical use of 5-HT_{1B/1D} receptor agonists and partial agonists for the prevention or alleviation of pain in the ear.

10 Background of the Invention

Pain is a perceived nociceptive response to local stimuli in the body. The perception of pain at the level of the central nervous system requires the transmission of painful stimuli by peripheral sensory nerve fibers. Upon stimulation of tissue (i.e., thermal, mechanical or
15 chemical), electro-chemical signals are transmitted from the sensory nerve endings to the spinal column, and hence to the brain where pain is perceived.

The ear is highly innervated with sensory afferents capable of transmitting various painful stimuli to the central nervous system. The ear is comprised of outer, middle and inner ear portions and otic pain may arise in any of these portions of the ear. Pain conditions
20 involving the ear, therefore, can arise in numerous instances, such as: foreign body stimulus, inflammation, edema, otic congestion, otic pressure, infection, accidental trauma, surgical procedures and post-surgical recovery.

The outer or "external" ear is comprised of the pinna and external ear canal ("EAC"). The EAC is a tubular, slightly curved structure extending from the pinna to the tympanic
25 membrane or "ear drum." Sound travels through the EAC and causes the tympanic membrane to vibrate. Various disorders can arise in the outer ear eliciting pain to the host. For example, otitis externa is an acute, painful inflammatory condition of the EAC that

WO 01/15677

PCT/US00/22764

affects all age groups of humans and accounts for roughly half of the ear pain pathologies known to exist. During the summer months, cases of otitis externa tend to increase due to what is known as "swimmer's ear." Swimmer's ear generally arises from the seepage of water into the EAC during swimming and the onset of infection and pain. Other outer ear disorders causing pain to the host include insertion of foreign objects in the ear, cerumen impaction, long-term use of hearing aids, and dermatological disorders, including psoriasis, eczema and seborrhea.

The middle ear is an air-filled cavity between the outer and inner ears. The middle ear is separated from the outer ear by the tympanic membrane and abuts the inner ear. It has a volume of about two milliliters and is connected to the back of the throat via the eustachian tube. The middle ear contains the malleus, incus and stapes, which are tiny bones that translate the movement of the tympanic membrane to the inner ear. Various conditions of the middle ear can cause pain to the host. For example, otitis media, which can be acute ("AOM") or associated with effusion ("OME"), is an inflammatory condition of the middle ear which generally affects children more often than adults (Karver, *Otitis Media, Primary Care*, Volume 25, No. 3, pages 619-632 (1998)). The etiology of otitis media is fairly broad and can be caused by various inflammatory events including infection and allergy. Effusion, which can be sterile or contain infectious material, may also result from otitis media. The fluid consists of various inflammatory cells (white blood cells), mediators of allergy and inflammation and cellular debris.

The inner ear comprises the sensory organs of the auditory and vestibular systems. It consists of two major compartments, known as the bony and membranous labyrinths. These chambers are highly organized and sensitive tissues and provide both auditory perception and

WO 01/15677

PCT/US00/22764

balance to the animal. Various pathologies may arise in the inner ear, creating distortion of hearing, loss of balance and pain.

Since otic pain is often associated with infection and resultant congestion and pressure, the primary therapeutic approach to treating otic pain is the administration of
5 antibiotics, both systemically and topically.

Various other therapies have been attempted for the alleviation of otic pain. Topical steroids (e.g., hydrocortisone) and systemic non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, have been used typically in conjunction with anti-infectives to treat otic pain.

10 Local anesthetics are another class of compounds which relieve pain by directly inhibiting nerve cellular function. A drawback of local anesthetic therapy is the short duration of action of such drugs. Another problem with the use of local anesthetics is that their mechanism of action, non-specific membrane stabilization, can have the undesired coincident effect of also inhibiting biological functions of cells, such as fibroblasts and
15 surrounding neural cells. Therefore, even though pain sensation can be abated with local anesthetic treatment, healing and normal function of the tissue may be significantly compromised. There is a need, therefore, to discover agents which potently and specifically inhibit the transmission of painful stimuli by sensory afferents, following local otic application.

20 Opiates are a class of compounds with well documented clinical analgesic efficacy. Opiates can be administered in a number of ways. For example, opiates can be administered systematically, by intravenous injection or oral dosage, or locally, by subcutaneous, intramuscular or topical application. Systemic administration of opiates, however, has been

WO 01/15677

PCT/US00/22764

associated with several problems including dose escalation (tolerance), addiction, respiratory depression and constipation.

Other agents have also been suggested for use in treating pain. Such agents include tricyclic antidepressants such as imipramine and desipramine, alpha-2 adrenergic agonists, serotonin uptake blockers, such as prozac, and other analgesics such as paracetamol, as described in United States Patent No. 5,270,050 (Coquelet et al.). Some of these therapies, however, have been associated with side-effects such as dryness of mouth, drowsiness, constipation, and low potencies and efficacies.

A class of agents which potently and specifically inhibit the transmission of painful stimuli by sensory afferents without local anesthetic activity following local otic application has yet to be described.

Serotonin, or 5-hydroxytryptamine ("5-HT"), is an endogenous peripheral and central neurotransmitter. Activation of serotonin receptors elicits the transduction of specific intracellular signals which lead to various physiological responses, depending on the receptor sub-type activated and the tissue stimulated. Certain classes of molecules have been discovered which bind to 5-HT receptors and either elicit 5-HT agonist or antagonist responses. Researchers have pursued the use of various 5-HT receptor agonists and antagonists in an effort to modulate cellular activity, and hence, effect various therapies to the afflicted tissues.

A number of different sub-types of 5-HT receptors have been discovered, based on differential agonist/antagonist sensitivities, second messenger coupling and protein structures. Such sub-types include, for example, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{1A} and 5-HT_{2A} (Hoyer et al., *VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)*, Pharmacological Reviews, volume 46, No. 2, Pages 157-170 (1994)). While all

WO 01/15677

PCT/US00/22764

serotonin receptors bind serotonin, different sub-types of serotonin receptors, which demonstrate a selective sensitivity to different agonists and antagonists, exist in various tissues and species. As noted by Hoyer et al. (1994), there are significant differences in the types of serotonin receptors evident among various species. For example, the 5-HT_{1B} receptor exists in rodents, while the homolog of this receptor, the pharmacologically defined 5-HT_{1D} receptor, exists in canine, pig and human species (Adham et al., *The Rat 5-Hydroxytryptamine_{1B} Receptor Is the Species Homologue of the Human 5-Hydroxytryptamine_{1D} Receptor*, Molecular Pharmacology, volume 41, pages 1-7 (1992) and Hoyer et al., *VII. International Union of Pharmacology Classification of Receptors for 5-Hydroxytryptamine (Serotonin)*, Pharmacological Reviews, volume 46, no. 2, pages 157-170 (1994)).

Numerous therapeutic approaches involving the manipulation of various serotonin receptors have been attempted. For example, the use of 5-HT₃ antagonists to treat emesis in cancer chemotherapy patients is disclosed in U.S. Patent No. 5,446,050 (Rosen); the use of certain 5-HT₁ agonists to treat a myriad of ailments is disclosed in U.S. Patent No. 5,409,941 (Nowakowski); and the use of 5-HT₂ antagonists to treat CNS disorders such as anxiety have been disclosed in U.S. Patent No. 5,393,761 (Perregaard et al.). However, nowhere in these publications has it been disclosed to use 5-HT_{1B} or 5-HT_{1D} agonists for the treatment of otic pain.

20

Summary of the Invention

The present invention is directed to compositions and methods of treating otic pain. More specifically, the present invention provides compositions containing 5-HT_{1D} and/or 5-

WO 01/15677

PCT/US00/22764

HT_{1B} agonists for the treatment of otic pain. The present invention is also directed to compositions comprising combinations of 5-HT_{1D} and/or HT_{1B} agonists and other pharmaceutical agents (i.e., anti-microbial agents, anti-inflammatory agents or anti-allergy agents) and methods of use.

5 The methods of the present invention involve the topical otic or intranasal application of the compositions of the present invention. One advantage of this therapy is that the inhibition of pain is receptor-specific, as contrasted with non-specific therapy, such as local anesthetic treatment. This specific activity may reduce greatly the number of dosings per day, and also reduce the drawbacks of short duration of action and inhibition of wound
10 healing which are associated with local anesthetics. Additionally, serotonin receptor binding agents acting locally within otic tissue avoid the problems of tolerance, addiction and constipation associated with the chronic, systemic administration of opiates.

Detailed Description of the Invention

15 The present invention is directed to the use of 5-HT_{1D} and/or 5-HT_{1B} receptor agonists for the prevention or alleviation of otic pain. The 5-HT_{1D} ("1D") receptor is found in human tissue such as cerebral arteries and parts of the brain, such as the basal ganglia, raphe and the cerebral cortex (Hoyer et al., (1994)). The 5-HT_{1B} ("1B") receptor, thus far, has been found
20 in the CNS and peripheral nerves of other species such as rat, mouse and hamster. However, the 1B receptor has been shown to possess similar homology, and thus similar sensitivity, as the 1D receptor (Hoyer et al., (1994)). It has now been found that 1B receptor agonists will activate 1D receptors. It is believed that the 5-HT_{1B} and/or 5-HT_{1D} receptors are present in otic tissue.

WO 01/15677

PCT/US00/22764

The compounds of the present invention are 1D agonists, 1B agonists or 1B/1D agonists. As used herein, a "1B agonist" refers to a compound which activates a 1B receptor, a "1D agonist" refers to a compound which activates a 1D receptor, and a "1B/1D agonist" refers to a compound which activates either a 1B or a 1D receptor.

5 Preferred 1B/1D agonists of the present invention are: 7-trifluoromethyl-4(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline maleate (CGS-12066A); Anpirtoline; RU-24969; 5-carboxamidotryptamine (5-CT); 5-methoxy-n,n,dimethyl-tryptamine; 1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-,butanedioate (Sumatriptan (GR43175C)); Methanesulfonamide,N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl] (L-694247); Metergoline; LY165163 (PAPP); BMS-180048; 10 PNU-142633; 1H-2-Benzopyran-6-carboxamide, 3,4-dihydro-1-[2-[4-(4-methoxyphenyl)-1-piperazinyl]ethyl]-N-methyl-, (S) -, (PNU-109291); 5(R)-(methylamino)-2,4,5,6-tetrahydro-1H-imidazo[4,5,1-ij]-quinolin-2-onemaleate (PNU-95666); N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-phenylethyl)-1-piperazinecarboxamidine (F-14258); F-12640, which
15 is a 4-aryl-1-(tryptamine-5-0-carboxymethyl)-piperazide; ALX-0646; 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R) (frovatriptan); 1H-Indole, 3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-(R) (eletriptan); Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl) (almotriptan); 1H-Indole-3-ethanamine,N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-,monobenzoate (rizatriptan
20 benzoate); 1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl) (naratriptan); 2-Oxazolidinone, 4-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S) (zolmitriptan); Glycinamide, N-[[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-L-tyrosyl- (IS-159); 1'-Methyl-5-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-biphenyl-4-ylcarbonyl]-2,3,6,7-tetrahydro-5H-spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289); L-782097; 3-[3-

WO 01/15677

PCT/US00/22764

[4-(5,6-Dimethoxypyrimidin-4-yl)piperazin-1-yl]propyl]-N-methyl-1H-indol-5-ylmethylsulfonamide (VS-395); (R)-N-methyl-[3-(1-methyl-2-pyrrolidinyl)-1H-indol-5-yl]methanesulphonamide (CP-122288); 3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]-propyl]-N-methyl-1H-indole-5-ylmethanesulfonamide (avitriptan); Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl) (eltoprazine); N-[3-(2-dimethylamino)ethoxy-4-methoxyphenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-(1,1'-biphenyl)-4-carboxamide (SB-216641); and 3-[4-(3-chlorophenyl)piperazin-1-yl]-1,1-diphenyl-2-propanol (BRL-15572).

Other classes of 1B/1D agonists have been suggested or are known in the art and may be useful in the present invention. For example, U.S. Patent Nos. 5,504,104 (Glennon) and 5,252,749 (Badorc et al.) disclose tryptamine analogs and thienocyclopentanone oxime ethers, respectively, and WIPO Patent Publication No. WO 95/14004 (Halazy et al.) discloses azylpiperazines, for use as 1B/1D agonists; the foregoing patents and publication are incorporated herein by reference to the extent they disclose 1B, 1D or 1B/1D agonists and methods of preparation or attainment. The 1B/1D agonists of the present invention are available from commercial sources or may be synthesized by methods known to those skilled in the art.

The 1B/1D agonists of the present invention may also be elucidated by employing standard methods known in the art. For example, the 1B/1D compounds may be ascertained by using radioligand binding assays to determine drug affinities at the 5HT_{1B/D} receptor such as those described in Hoyer, et al., *Characterization of the 5HT_{1B} recognition sites in rat brain: binding studies with (-)-[¹²⁵I]cyanopindolol*, Eur. J. Pharmacol., volume 118, pages 1-12 (1985). The 1B/1D compounds may also be determined using a number of functional *in vitro* assays. Common assays include methods involving the inhibition of forskolin-induced

WO 01/15677

PCT/US00/22764

adenylyl cyclase activity in (1) cells that naturally express the 5HT_{1B/D} receptor (e.g., in Chinese hamster ovary cells as described in Giles, et al., *Characterization of a 5HT_{1B} receptor in CHO cells: functional responses in the absence of radioligand binding*, Br. J. Pharmacol., volume 117, pages 1119-1126 (1996)), and (2) in host cells genetically engineered to express recombinant human or animal 5HT_{1B/D} receptors (e.g., Price, et al., *SB-216641 and BRL-15572 compounds to pharmacologically discriminate h5HT_{1B} and h5HT_{1D} receptors*, Naunyn-Schmiedeberg's Arch. Pharmacol., volume 356, pages 312-320 (1997)). In addition, intercellular Ca²⁺-mobilization assays have also been employed to determine the efficacy of 1B/1D compounds for agonist activity at the 5HT_{1B/D} receptor (Dickenson and Hill, *Coupling of an endogenous 5HT_{1B}-like receptor to increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells*, Br. J. Pharmacol., volume 116, pages 2889-2896 (1995)). Assays involving the functional activity *in-vivo* at the 5HT_{1B/D} receptor are also useful for the determination 1B/1D compounds. For example, Matsubara et al. describe a method to elucidate 1B/1D compounds using the electrically-induced neurogenic plasma extravasation from the brain dura matter by stimulation of the trigeminal ganglion (Matsubara, et al., *CP-93,129, a potent and selective 5HT_{1B} receptor agonist blocks neurogenic plasma extravasation within rat but not in guinea pig dura matter*, Br. J. Pharmacol., volume 104, pages 3-4 (1991)).

The 1B/1D agonists of the present invention will be contained in topical or intranasal compositions, in accordance with formulation techniques known to those skilled in the art. The compounds may be included in solutions, suspensions, aerosols and other dosage forms adapted for the particular 1B/1D agonist and dosing regimen.

The 1B/1D compounds will be contained in compositions of the present invention in concentrations effective to prevent or ameliorate otic pain. As used herein, the term

WO 01/15677

PCT/US00/22764

"pharmaceutically effective amount" refers to that amount of one or more 1B/1D agonists which prevents or alleviates otic pain. Generally, the dosage of 1B/1D agonists utilized for any of the uses described herein will be from about one to two drops of a 0.01 to 3% weight/volume ("w/v") composition, or corresponding amount for aerosol application, administered one to
5 four times per day.

The present invention is particularly directed to the provision of compositions adapted for topical treatment of otic tissues. The compositions may also be adapted for administration intranasally for treatment of otic tissues, such as nasal drops or an aerosol composition. The otic compositions of the present invention will include one or more 1B/1D agonists and a
10 pharmaceutically acceptable vehicle for these agonist(s). Various types of vehicles may be used. The vehicles will generally be aqueous in nature. Aqueous solutions or suspensions are generally preferred, based on ease of formulation, as well as a patient's ability to easily administer such compositions by means of instilling one to two drops of the solutions in the affected ears. However, the compounds of the present invention may also be readily
15 incorporated into other types of compositions, such as aerosols (intranasal or intraotic), suspensions, viscous or semi-viscous gels or other types of solid or semi-solid compositions. Suspensions may be preferred for 1B/1D agonists which are relatively insoluble in water.

As stated above, the compositions of the present invention may also contain additional pharmaceutically active agents or may be dosed concurrently with other pharmaceutical
20 compositions.

In particular, when treating a mammal for the prevention, treatment or amelioration of otic infection, the compositions of the present invention may also contain one or more antibiotic, antiviral and/or antifungal agents (hereinafter collectively referred to as "anti-microbial agents") or may be dosed concurrently or sequentially with anti-microbial agent

WO 01/15677

PCT/US00/22764

containing compositions. Examples of anti-microbial agents include, but are not limited to, chlorempenicol, ofloxacin, norfloxacin, lomefloxacin, ciprofloxacin, natamycin, neomycin, polymyxin B, gentamycin, tobramycin, bacitracin, gramicidin, erythromycin, moxifloxacin, oxazolidinones, trovafloxacin, grepafloxacin, sulfacetamide, tetracycline, sulfisoxazole, diolamine, trifluorothymidine, acyclovir, gancyclovir, vaniomycin or other antibiotic, antiviral and antifungal agents known to those skilled in the art. The 1B/1D agonist/anti-microbial agent combination compositions will contain one or more 1B/1D agonists, as stated above, and one or more anti-microbial agents in an amount effective to prevent, treat or ameliorate otic infection. As used herein, such an amount is referred to as "an effective amount of one or more anti-microbial agents" or "an amount effective to prevent, treat or ameliorate otic infection." In general, however, the 1B/1D agonist/anti-microbial combination compositions of the present invention will typically contain one or more antibiotics in an amount of about 0.05 to 3.0 % w/v.

When treating a mammal for the prevention, treatment or amelioration of otic allergic reactions and responses, the compositions of the present invention may also contain one or more anti-allergy agents, histamine H₁ receptor antagonists or anti-histaminic agents (hereinafter collectively referred to as "anti-allergy agents"), or may be dosed concurrently or sequentially with anti-allergy agent containing compositions. Examples of anti-allergy agents include, but are not limited to, mizolastine, mapinastine, levocabastine, pheniramine, antazoline, ketotifen, azelastine, doxepine analogs, such as those described in U.S. Patent Nos. 4,871,865 (Lever et al.) and 4,923,892 (Lever et al.), cetirizine, loratadine, fenoxifenadine, diphenhydramine, brompheniramine, chlorpheniramine, clemastine, pyrilamine, cromolyn, nedocromil, lodoxamide, or other anti-allergy agents known to those skilled in the art. The 1B/1D agonist/anti-allergy agent combination compositions will contain

WO 01/15677

PCT/US00/22764

one or more 1B/1D agonists, as stated above, and one or more anti-allergy agents in an amount effective to prevent, treat or ameliorate otic allergic reactions and responses. As used herein, such an amount is referred to as "an effective amount of one or more anti-allergy agents" or "an amount effective to prevent, treat or ameliorate otic allergic reactions or responses." In
5 general, however, the 1B/1D agonist/anti-allergy agent combination compositions of the present invention will typically contain one or more anti-allergy agents in an amount of about 0.001 to 1.0 % w/v.

When treating a mammal for the prevention, treatment or amelioration of otic inflammatory reactions and responses, the compositions of the present invention may also
10 contain one or more anti-inflammatory agents or may be dosed concurrently or sequentially with anti-inflammatory agent containing compositions. Examples of anti-inflammatory agents include, but are not limited to, PAF antagonists, such as SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant, E-6123, BN-50727, nupafant and modipafant; PDE IV inhibitors, such as ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-
15 1088, V-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004, and roflumilast; cyclooxygenase type I and II inhibitors, such as nepafenac, amfenac, diclofenac, flurbiprofen, indomethacin, naproxen, ketorolac, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, suprofen, mefanamic acid, diflusal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetone, etodolac, phenylbutazone,
20 aspirin, oxyphenbutazone, NCX-4016, HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; cyclooxygenase type II selective inhibitors, such as NS-398, viox, celecoxib, P54, etodolac, darbufelone mesylate, L-804600 and S-33516; and inhibitors of cytokine production, such as inhibitors of the NFkB transcription factor; or other anti-inflammatory agents known to those skilled in the art. The 1B/1D agonist/anti-inflammatory agent

WO 01/15677

PCT/US00/22764

combination compositions will contain one or more 1B/1D agonists, as stated above, and one or more anti-inflammatory agents in an amount effective to prevent, treat or ameliorate otic inflammatory reactions and responses. As used herein, such an amount is referred to as "an effective amount of one or more anti-inflammatory agents" or "an amount effective to prevent, 5 treat or ameliorate otic inflammatory reactions or responses." In general, however, the 1B/1D agonist/anti-inflammatory agent combination compositions of the present invention will typically contain one or more anti-inflammatory agents in an amount of about 0.01 to 1.0 % w/v.

The otic compositions of the present invention may also include various other 10 ingredients, such as buffers, preservatives, co-solvents and viscosity building agents.

An appropriate buffer system (e.g., sodium phosphate, sodium acetate or sodium borate) may be added to prevent pH drift under storage conditions.

Otic products are typically packaged in multidose form. Preservatives are thus required in multidose compositions to prevent microbial contamination during use. Suitable 15 preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium-1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001 to 1.0 % w/v.

Some of the compounds of the present invention may have limited solubility in water 20 and therefore may require a surfactant or other appropriate co-solvent in the composition. Such co-solvents include: polyethoxylated castor oils, Polysorbate 20, 60 and 80; Pluronic® F-68, F-84 and P-103 (BASF Corp., Parsippany NJ, USA); cyclodextrin; or other agents known to those skilled in the art. Such co-solvents are typically employed at a level of from 0.01 to 2% w/v.

WO 01/15677

PCT/US00/22764

Viscosity greater than that of simple aqueous solutions may be desirable to increase otic absorption of the active compound, to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation and/or otherwise to improve the otic formulation. Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose or other agents known to those skilled in the art. Such agents are typically employed at a level of from 0.01 to 2% w/v.

The compositions may also be used for treating irritated tissues following otic surgery. The compositions may be used for acute treatment of temporary conditions, or may be administered chronically. The compositions may also be used prophylactically, especially prior to otic surgery or noninvasive otic procedures, or other types of surgery.

As stated above, the compounds and compositions of the invention will be used to prevent or ameliorate otic pain associated with various stimuli. For example, the 1B/1D agonists and compositions of the present invention may be used in treating pain arising from allergens, inflammation, trauma, congestion, infection, foreign body sensation and surgery, e.g., following cochlear implant surgery. With such treatment, the 1B/1D agonists can be individually dosed, or in combination with other pharmaceutical agents known in the art.

The compositions of the present invention are further illustrated by the following formulation examples 1-4. The ingredient "1B/1D agonist" denotes a compound of the present invention.

WO 01/15677

PCT/US00/22764

Example 1

The following is an example of an otic/nasal solution:

5	Ingredient	Amount (% w/v)
10	7-trifluoromethyl-4(4-methyl-1-piperazinyl) -pyrrolo[1,2-a]quinoxaline maleate (CGS-12066A)	0.01-1.0
	Phosphate Buffered Saline	1.0
	Polysorbate 80	0.5
15	Purified water	q.s. to 100%

Example 2

The following is an example of an otic/nasal suspension:

25	Ingredient	Amount (% w/v)
	1B/1D agonist	0.01-1.0
	Monobasic sodium phosphate	0.05
	Dibasic sodium phosphate (anhydrous)	0.15
	Sodium chloride	0.75
30	Disodium EDTA (Edetate disodium)	0.05
	Cremophor EL	0.1
	Benzalkonium chloride	0.01
	HCl and/or NaOH	pH 7.3 - 7.4
35	Purified water	q.s. to 100%

WO 01/15677

PCT/US00/22764

Example 3

5 The following is an example of an otic/nasal suspension or solution:

Ingredient	Amount (% w/v)
1B/1D agonist	0.01-1.0
10 Phosphate Buffered Saline	1.0
Hydroxypropyl- β -cyclodextrin	4.0
Purified water	q.s. to 100%

15

Example 4

20 The following is an example of an otic/nasal suspension:

Ingredient	Amount (% w/v)
1B/1D agonist	0.1-1.0
25 Moxifloxacin	0.3
Benzalkonium Chloride	0.01
Edetate Disodium, USP	0.01
Sodium Chloride, USP	0.3
Sodium Sulfate, USP	1.2
30 Tyloxapol, USP	0.05
Hydroxyethylcellulose	0.25
Sulfuric Acid and/or	
Sodium Hydroxide, NF	q.s.
Purified Water, USP	q.s. to 100%

35

WO 01/15677

PCT/US00/22764

What is claimed is:

1. A topical otic or intranasal composition for treating otic pain comprising a pharmaceutically effective amount of one or more 1B/1D agonist(s) in a pharmaceutically acceptable vehicle.
2. A composition according to Claim 1, wherein the 1B/1D agonist is selected from the group consisting of: CGS-12066A; Anpirtoline; RU-24969; 5-carboxamidotryptamine; 5-methoxy-n,n,dimethyl-tryptamine; Sumatriptan; L-694247; Metergoline; LY165163; BMS-180048; PNU-142633; PNU-109291; PNU-95666; F-14258; F-12640; ALX-0646; frovatriptan; eletriptan; almotriptan; rizatriptan benzoate; naratriptan; zolmitriptan; IS-159; SB-224289; L-782097; VS-395; CP-122288; avitriptan; eltoprazine; BRL-15572; and SB-216641.
3. A composition according to Claim 2, wherein the 1B/1D agonist is 7-trifluoromethyl-4(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline maleate.
4. A composition according to Claim 2, wherein the 1B/1D agonist is Anpirtoline.
5. A composition according to Claim 1, wherein the composition also comprises one or more an anti-microbial agents in an amount effective to prevent, treat or ameliorate otic infections.
6. A composition according to Claim 1, wherein the composition also comprises one or more an anti-allergy agents in an amount effective to prevent, treat or ameliorate otic allergy reactions or responses.
7. A composition according to Claim 1, wherein the composition also comprises one or more an anti-inflammatory agents in an amount effective to prevent, treat or ameliorate otic inflammatory reactions or responses.

WO 01/15677

PCT/US00/22764

8. A composition according to Claim 5, wherein the anti-microbial agent(s) is/are selected from the group consisting of: chlorempenicol, ofloxacin, norfloxacin, lomefloxacin, ciprofloxacin, natamycin, neomycin, polymyxin B, gentamycin, tobramycin, bacitracin, gramicidin, erythromycin, moxifloxacin, oxazolidinones, trovafloxacin, grepafloxacin, 5 sulfacetamide, tetracycline, sulfisoxazole, diolamine, trifluorothymidine, acyclovir, gancyclovir and vaniomycin.

9. A composition according to Claim 6, wherein the anti-allergy agent(s) is/are selected from the group consisting of: mizolastine, mapinastine, levocabastine, pheniramine, 10 antazoline, ketotifen, azelastine, doxepine analogs, cetirizine, loratadine, fenoxifenadine, diphenhydramine, brompheniramine, chlorpheniramine, clemastine, pyrilamine, cromolyn, nedocromil and lodoxamide.

10. A composition according to Claim 7, wherein the anti-inflammatory agent(s) 15 is/are selected from the group consisting of: PAF antagonists; PDE IV inhibitors; cyclooxygenase type I and II inhibitors; cyclooxygenase type II selective inhibitors; and inhibitors of cytokine production.

11. A composition according to Claim 10, wherein the PAF antagonists are 20 selected from the group consisting of SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant, E-6123, BN-50727, nupafant and modipafant; the PDE IV inhibitors are selected from the group consisting of ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-1088, V-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004 and roflumilast; the cyclooxygenase type I and II inhibitors 25 are selected from the group consisting of nepafenac, amfenac, diclofenac, flurbiprofen, indomethacin, naproxen, ketorolac, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, suprofen, mefanamic acid, diflusal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, NCX-4016, HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; the cyclooxygenase type II 30 selective inhibitors are selected from the group consisting of NS-398, viox, celecoxib, P54, etodolac, darbufelone mesylate, L-804600 and S-33516; and the inhibitors of cytokine

WO 01/15677

PCT/US00/22764

production are selected from the group consisting of inhibitors of the NFkB transcription factor.

12. A method for treating otic pain which comprises administering to a mammal a topical or intranasal composition comprising a pharmaceutically effective amount of one or more 1B/1D agonists in a pharmaceutically acceptable vehicle.

13. A method according to Claim 12, wherein the 1B/1D agonist is selected from the group consisting of: CGS-12066A; Anpirtoline; RU-24969; 5-carboxamidotryptamine; 5-methoxy-n,n,dimethyl-tryptamine; Sumatriptan; L-694247; Metergoline; LY165163; BMS-180048; PNU-142633; PNU-109291; PNU-95666; F-14258; F-12640; ALX-0646; frovatriptan; eletriptan; almotriptan; rizatriptan benzoate; naratriptan; zolmitriptan; IS-159; SB-224289; L-782097; VS-395; CP-122288; avitriptan; eltoprazine; BRL-15572; and SB-216641.

14. A method according to Claim 13, wherein the 1B/1D agonist is 7-trifluoromethyl-4(4-methyl-1-piperazinyl)-pyrrolo[1,2-a]quinoxaline maleate.

15. A method according to Claim 14, wherein the 1B/1D agonist is Anpirtoline.

16. A method according to Claim 12, further comprising administering the composition topically to the ear or intranasally.

17. A method according to Claim 13, further comprising administering the composition topically to the ear or intranasally.

18. A method according to Claim 12, wherein the otic pain is caused by otitis media, otitis externa, otic surgery or swimmer's ear.

WO 01/15677

PCT/US00/22764

19. A method according to Claim 12, wherein the composition further comprises one or more anti-microbial agents in an amount effective to prevent, treat or ameliorate otic infections.

5 20. A method according to Claim 12, wherein the composition further comprises one or more anti-allergy agents in an amount effective to prevent, treat or ameliorate otic allergic reactions or responses.

21. A method according to Claim 12, wherein the composition further comprises
10 one or more anti-inflammatory agents in an amount effective to prevent, treat or ameliorate otic inflammatory reactions or responses.

22. A method according to Claim 19, wherein the anti-microbial agent(s) is/are selected from the group consisting of: chlorempenicol, ofloxacin, norfloxacin, lomefloxacin,
15 ciprofloxacin, natamycin, neomycin, polymyxin B, gentamycin, tobramycin, bacitracin, gramicidin, erythromycin, moxifloxacin, oxazolidinones, trovafloxacin, grepafloxacin, sulfacetamide, tetracycline, sulfisoxazole, diolamine, trifluorothymidine, acyclovir, gancyclovir and vaniomycin.

20 23. A method according to Claim 20, wherein the anti-allergy agent(s) is/are selected from the group consisting of: mizolastine, mapinastine, levocabastine, pheniramine, antazoline, ketotifen, azelastine, doxepine analogs, cetirizine, loratadine, fenoxifenadine, diphenhydramine, brompheniramine, chlorpheniramine, clemastine, pyrillamine, cromolyn, nedocromil and lodoxamide.

25

24. A method according to Claim 21, wherein the anti-inflammatory agent(s) is/are selected from the group consisting of: PAF antagonists; PDE IV inhibitors; cyclooxygenase type I and I inhibitors; cyclooxygenase type II selective inhibitors; and inhibitors of cytokine production.

30

25. A method according to Claim 24, wherein the PAF antagonists are selected from the group consisting of SR-27417, A-137491, ABT-299, apafant, bepafant, minopafant,

WO 01/15677

PCT/US00/22764

E-6123, BN-50727, nupafant and modipafant; the PDE IV inhibitors are selected from the group consisting of ariflo, torbafylline, rolipram, filaminast, piclamilast, cipamfylline, CG-1088, V-11294A, CT-2820, PD-168787, CP-293121, DWP-205297, CP-220629, SH-636, BAY-19-8004 and roflumilast; the cyclooxygenase type I and I inhibitors are selected from
5 the group consisting of nepafenac, amfenac, diclofenac, flurbiprofen, indomethacin, naproxen, ketorolac, ibuprofen, bromfenac, ketoprofen, meclofenamate, piroxicam, sulindac, suprofen, mefanamic acid, diflusal, oxaprozin, tolmetin, fenoprofen, benoxaprofen, nabumetome, etodolac, phenylbutazone, aspirin, oxyphenbutazone, NCX-4016, HCT-1026, NCX-284, NCX-456, tenoxicam and carprofen; the cyclooxygenase type II selective
10 inhibitors are selected from the group consisting of NS-398, vioxx, celecoxib, P54, etodolac, darbufelone mesylate, L-804600 and S-33516; and the inhibitors of cytokine production are selected from the group consisting of inhibitors of the NFkB transcription factor.

26. A method according to Claim 19, wherein the otic pain is caused by otitis
15 media, otitis externa, otic surgery or swimmer's ear.

27. A method according to Claim 22, wherein the otic pain is caused by otitis media, otitis externa, otic surgery or swimmer's ear.